Core Insights - Propanc Biopharma, Inc. has entered into a securities purchase agreement with Hexstone Capital LLC for a private placement of up to $100 million in convertible preferred stock to support its digital asset acquisition strategy and accelerate its R&D pipeline [1][2] - The initial investment of $1 million was received upon closing, based on the issuance of 100 shares of Series C Convertible Preferred Stock, each with a par value of $0.01 and an initial stated value of $10,000 [1] - The company plans to enter a First-In-Human study for its lead product candidate, PRP, in the second half of 2026 [1] Financial Details - Propanc will issue 9,900 Warrants to Hexstone, each allowing the purchase of one share of Preferred Stock at $10,000 per share, totaling up to $99 million in potential funding [2] - The Warrants are immediately exercisable and valid for 12 months, with the company able to call up to 500 Warrants per calendar month at $0.01 each, allowing for the exercise of up to $5 million in Preferred Stock per month [2] Company Overview - Propanc Biopharma, Inc. is focused on developing treatments to prevent recurrence and metastasis in cancer patients by targeting cancer stem cells through proenzyme activation [4] - The company's lead product candidate, PRP, aims to address the root cause of cancer proliferation and spread [4]

MELBOURNE, Australia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced that it has entered into a securities purchase agreement with Hexstone Capital LLC ("Hexstone"), a family office that has invested in a significant number of Digital Asset Treasury (DAT) companies across a range of digital assets including BTC, ETH, SOL, D ...